Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Filip Janku


United States of America

The University of Texas,
MD Anderson Cancer Center
Houston, Texas

Dr Filip Janku, MD, PhD is an Associate Professor in the Department of Investigational Cancer Therapeutics (Phase I Program) at MD Anderson Cancer Center.

Dr Janku obtained his MD and PhD at the Charles University Prague. He joined the Department of Investigational Cancer Therapeutics in the 2011 after completion of the drug development fellowship at the same institution.

Dr Janku is a principal investigator for numerous phase I trials, most of which involve novel, targeted agents, many of those being novel first-in-human studies; he received multiple awards for his research efforts, including the Khalifa award, Sidney Kimmel Scholar award, several ASCO Merit Awards as well as an American Association for Cancer Research Scholar-in-Training Award.

Dr Janku has published over 170 articles in peer-reviewed journals and his academic research interests focus on proof-of-concept clinical trials that possess a pivotal correlative component especially those involving liquid biopsies, molecular profiling of cell-free DNA, the PI3K/AKT/mTOR, MAPK, IDH pathways and therapeutic use of oncolytic bacteria. 

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.